Literature DB >> 16463052

Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome.

Nicola Strnad-Trojan1, Richard Linde, Janine Reichenbach, Jörg Trojan, Stefan Zeuzem, Stefan Zielen.   

Abstract

Chronic hepatitis C (HCV) infection in patients with primary immunodeficiency increases the risk of an accelerated progression of HCV-related liver disease. Here, we report a patient with X-linked lymphoproliferative syndrome infected with HCV and Epstein-Barr virus (EBV). After combination treatment with interferon alpha-2b and ribavirin, clearance of HCV-RNA was achieved, and noteworthily, EBV DNA also became undetectable.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16463052     DOI： 10.1007/s00431-005-0062-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  12 in total

1.  Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C.

Authors:  H M Chapel; J M Christie; V Peach; R W Chapman
Journal:  Clin Immunol       Date:  2001-06       Impact factor: 3.969

2.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

3.  Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia.

Authors:  K Bjøro; K Skaug; T Haaland; S S Frøland
Journal:  QJM       Date:  1999-08

Review 4.  Epstein-Barr virus infections: prospects for treatment.

Authors:  Edward Gershburg; Joseph S Pagano
Journal:  J Antimicrob Chemother       Date:  2005-07-08       Impact factor: 5.790

5.  Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency.

Authors:  S Razvi; L Schneider; M M Jonas; C Cunningham-Rundles
Journal:  Clin Immunol       Date:  2001-12       Impact factor: 3.969

6.  Molecular genetic haplotype segregation studies in three families with X-linked lymphoproliferative disease.

Authors:  V Schuster; S Seidenspinner; T Grimm; W Kress; S Zielen; M Bock; H W Kreth
Journal:  Eur J Pediatr       Date:  1994-06       Impact factor: 3.183

7.  Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency.

Authors:  J W Gratama; M A Oosterveer; F E Zwaan; J Lepoutre; G Klein; I Ernberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 8.  NIH Consensus Statement on Management of Hepatitis C: 2002.

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Jun 10-12

9.  Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.

Authors:  K Bjøro; S S Frøland; Z Yun; H H Samdal; T Haaland
Journal:  N Engl J Med       Date:  1994-12-15       Impact factor: 91.245

10.  Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene.

Authors:  A J Coffey; R A Brooksbank; O Brandau; T Oohashi; G R Howell; J M Bye; A P Cahn; J Durham; P Heath; P Wray; R Pavitt; J Wilkinson; M Leversha; E Huckle; C J Shaw-Smith; A Dunham; S Rhodes; V Schuster; G Porta; L Yin; P Serafini; B Sylla; M Zollo; B Franco; A Bolino; M Seri; A Lanyi; J R Davis; D Webster; A Harris; G Lenoir; G de St Basile; A Jones; B H Behloradsky; H Achatz; J Murken; R Fassler; J Sumegi; G Romeo; M Vaudin; M T Ross; A Meindl; D R Bentley
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330
View more
  1 in total

Review 1.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.